Portland City Council President Pirtle-Guiney weighs in on cuts to mayor's proposed budget
Now it's up to Portland's new 12-person City Council to approve the budget, including president Elana Pirtle-Guiney from District 2.
Councilor Pirtle-Guiney — who represents North and Northeast Portland — has been a union organizer, a policy expert for the state, as well as a member of former Governor Kate Brown's executive team.
She joined this week's Eye on Northwest Politics to discuss tackling the proposed budget, her take on the mayor's proposed reductions, city workers' threats to strike and more.
Watch the full interview in the video above.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
2 hours ago
- New York Post
Adams trashes $14 M NYC Council-approved law to provide free garbage bins: 'Ax to grind'
NYC homeowners might not be getting the free garbage cans the City Council promised – as legislators and Mayor Eric Adams literally fight over trash. Adams revealed this week he won't sign off on $14.5 million in taxpayer dough to give away hundreds of thousands of specially secure bins to New Yorkers as part of his war on NYC rats. The bins are supposed to go to owners of one- and two-family homes with the city refunding those who already purchased them, provided they are enrolled in the state's School Tax Relief (STAR) program. The giveaway was supposed to begin Friday under legislation sponsored by Yusef Salaam (D-Manhattan) that the Council unanimously approved in February with a veto-proof majority. 3 Mayor Eric Adams is snubbing a new law that is supposed to provide owners of one- and two-family home with city-issued bins. Instead, Council members this week were told to come up with the $14.5 million on their own — enough to cover about 265,000 one-and two family households, by NYC Independent Budget Office estimates. The City Council has its own taxpayer-funded budget that it uses to pay staff, fund pet projects in their district and for other initiatives. It was the latest salvo fired in an ongoing feud between the city's executive and legislative branches, which also this week included Adams vetoing a City Council measure that would have blocked Bally's from opening a Bronx casino and another that would decriminalize illegal vending. 3 'The mayor has an ax to grind,' said Council Minority Leader Joann Ariola (R-Queens). Ron Sachs – CNP for NY Post A vast majority of NYC property owners will be required to use city-issued bins with secure lids by June 2026. They range in cost from $43.88 for 25-gallon containers to $53.01 to 45-gallon bins — a tab the Council believes should be picked up by the city for many New Yorkers. Reps for the mayor said the Council should have addressed the bill's funding before agreeing last month on a new $115.9 billion budget for this fiscal year – especially since Adams previously complained the trash-bin giveaway plan was fiscally irresponsible. But Adams has an obligation to abide by the new law, and the Council believed the money for the bins was covered by $32 million of permanent new funding he set aside for the Department of Sanitation to keep NYC clean, some members said. 'The mayor has an ax to grind … This was never supposed to be funded by the City Council,' said Council Minority Leader Joann Ariola (R-Queens). '[Adams] is putting up the middle-finger to middle-class taxpayers.' 3 The trash-bin giveaway was supposed to begin Friday under legislation sponsored by Yusef Salaam (D-Manhattan) Matthew McDermott 'Homeowners in the STAR program are predominantly seniors and one of the most vulnerable groups in the city. That's why the … legislation to provide free garbage bins to these residents was so important,' said Councilwoman Lynn Schulman (D-Queens). 'The city must take care of its most precious constituents.' Salaam did not return messages. Liz Garcia, an Adams spokeswoman, said 'it is unfortunate that the City Council irresponsibly passed an unfunded law and then did not prioritize funding for it during our recent budget negotiations.' 'We will continue to work to provide the most affordable options to New Yorkers and send the rats packing out of our city,' Garcia said.
Business Wire
3 hours ago
- Business Wire
RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501's clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event ('SAE'); (4) accordingly, RP-A501's safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
4 hours ago
- Yahoo
TransMedics Group, Inc. (TMDX): A Bull Case Theory
We came across a bullish thesis on TransMedics Group, Inc. on Global Equity Briefing's Substack by Ray Myers. In this article, we will summarize the bulls' thesis on TMDX. TransMedics Group, Inc.'s share was trading at $118.97 as of July 31st. TMDX's trailing and forward P/E were 59.75 and 62.11 respectively according to Yahoo Finance. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. TransMedics is revolutionizing the organ transplant ecosystem through its Organ Care System, a technology designed to keep organs warm, oxygenated, and viable far longer than traditional cold storage. By tackling key bottlenecks—organ degradation, low utilization rates, and logistical constraints—Organ Care System significantly extends transplant windows and boosts usage rates. Clinical trial data highlights its transformative potential: expanded criteria lungs and hearts saw utilization jump to 87% and 81%, respectively, while DCD heart use rose from 0% to 89%. TMDX monetizes this impact through a razor-and-blade model—selling Organ Care System consoles and high-margin, single-use consumables—while providing end-to-end services through its National Organ Care System Program, a SaaS-like Organs as a Service platform. With 21 private jets, 17 procurement hubs, and trained staff, TMDX handles organ retrieval, transport, and maintenance, positioning itself as a logistics powerhouse in the transplant chain. The opportunity is vast: U.S. underutilization alone represents a $400M+ annual consumables revenue potential, and TMDX currently serves just 3% of the $39B global market expected by 2034. Future growth catalysts include a kidney Organ Care System by 2029, entry into international markets via a $200M facility in Italy, and scaling the National Organ Care System Program globally. Financially, the company achieved profitability in 2024, posting $441M in revenue and positive operating cash flow, though free cash flow remains negative due to capex-heavy expansion. Trading at a P/E of 91, investor returns hinge on continued execution, EU rollout, and successful kidney platform launch. If goals are met, the stock could double by 2030, but slower expansion or margin compression may limit upside. Previously, we covered a on TransMedics Group, Inc. by Oliver | MMMT Wealth in May 2025, which highlighted warm perfusion technology, strong execution, and real-time flight data as revenue indicators. The company's stock appreciated ~24% since Q1 outperformance played out. Ray Myers shares a similar view but emphasizes the SaaS-like NOP model and global expansion potential. TransMedics Group, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held TMDX at the end of the first quarter which was 29 in the previous quarter. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
